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A recent systematic review, ‘Fibrinogen concentrate in bleeding
patients’, published by The Cochrane Collaboration, aimed to
assess the benefits and harms of fibrinogen concentrate com-
pared with placebo or other treatments in bleeding patients.1
We agree with the authors finding that fibrinogen concentrate
reduces transfusion requirements for allogeneic blood products,
as this is in linewithpreviouslypublished work.2 3 In addition, the
review did not identify any adverse events associated with
fibrinogen concentrate; again, this is in line with previous find-
ings.4 5 However, we feel that the reviewalso made a numberof
incorrect or misleading assertions which merit further discus-
sion and clarification.
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Firstly, the authors suggest that the use of fibrinogen con-
centrate should be confined ‘to a controlled clinical setting or
trial’, a suggestion that has been made previously by Stan-
worth and Hunt.6 However, if this principle were to be applied
routinely, it would lead to the abolition of all blood bank
products, including plasma and cryoprecipitate, until robust
trial data became available.7 This suggestion also ignores the
fact that the most widely available fibrinogen concentrate
has held a licence since 1963 in Brazil, since 1966 in Europe,
has been licensed in its current pasteurized form since 1985,
and is currently licensed for treatment of both congenital and
acquired fibrinogen deficiencies in Argentina, Austria, Brazil,
Bulgaria, the Czech Republic, Germany, Hungary, Iran, Kuwait,
the Netherlands, Portugal, Romania, Switzerland, Taiwan,
Tunisia, and Turkey.8 Indeed, a number of recent guidelines rec-
ommend the use of fibrinogen concentrate in the bleeding
patient, including the updated European trauma guidelines9
and the European Society of Anaesthesiology guidelines;10
both of these guidelines were published before the searches
for the Cochrane analysis were completed. It should also be
noted that fibrinogen concentrate has a licence for the treat-
ment of congenital deficiencies in Australia, Canada, Israel,
Mexico, New Zealand, Puerto Rico, the USA, and numerous EU
countries. Any off-label use in these countries (e.g. in the
setting of acquired bleeding) is at the discretion of the individ-
ual physician, taking into account the risk profile of the avail-
able alternative treatments.11
The authors of the Cochrane review also recommend not
using fibrinogen concentrate in the clinical setting until
further evidence is available. However, they give no suitable
recommendation of an alternative treatment. This negli-
gence could in fact endanger patients, as the alternatives
for fibrinogen supplementation, that is, fresh-frozen plasma
(FFP) and cryoprecipitate, are associated with a number of
adverse events.12 Furthermore, the efficacy and safety of
cryoprecipitate have never been tested in the setting of a ran-
domized controlled trial (RCT). A recent systematic review of
FFP found no consistent evidence or significant benefit for
its prophylactic or therapeutic use across a range of settings
in which it is indicated;13 FFP is also associated with increased
morbidity.14 Cryoprecipitate has been withdrawn from a
number of European countries in response to safety con-
cerns,15 and in most countries in which it is still available, it
is no longer used for hereditary bleeding disorders. In fact,
as acknowledged in the Cochrane review, fibrinogen concen-
trate is now preferred to both cryoprecipitate and FFP in the
hereditary setting, and so the continued use of these products
for the treatment of acquired bleeding disorders represents
a double standard.16 In 2009, the Irish Blood Transfusion
Service took the decision to withdraw cryoprecipitate and
replace it with fibrinogen concentrate, despite a lack of
formal licensing.17 This decision was made to reduce the
risk of pathogen transmission, and was supported by a lack
of evidence suggesting any benefit of cryoprecipitate over
fibrinogen concentrate.17 In addition, the World Health Or-
ganization recently urged member states to ‘promote the
availability of transfusion alternatives’.18 It is perhaps
unethical for the Cochrane group to suggest that a newer
treatment with a growing body of evidence should be
shunned in favour of older treatments which, despite being
in use since World War II, have never been proven orevaluated
according to the Cochrane methodology and are associated
with a number of safety concerns. Tradition should not
factor in the decision-making process in clinical practice,
and, in any case, one might argue that fibrinogen concentrate
is rapidly becoming the ‘traditional’ (standard of care) treat-
ment for acquired hypofibrinogenaemia in a number of coun-
tries, such as Austria, Germany, and Switzerland.19
A number of RCTs are currently taking place or are planned
to investigate the use of fibrinogen concentrate in settings
such as cardiac surgery and postpartum haemorrhage. Of
course, the evidence gathered from such trials can and should
be used to inform clinical practice in the future.20 However,
there are already numerous publications reporting the regular
use of fibrinogen concentrate, particularly in centres across
Europe.17 21 22 There has also been a focus on the use of algo-
rithmsto guide individualized dosing of fibrinogen, often driven
by point-of-care testing.21 22 As fibrinogen is the first coagula-
tion factor to decrease to critically low levels during haemor-
rhage,23 the use of fibrinogen concentrate allows targeted
replacement of a specific part of the coagulation cascade.
Relying on blanket therapies such as plasma or cryoprecipitate,
with all their associated risks, is taking a step backwards when
we should be moving forward into an era of targeted, persona-
lized medicine. Indeed, the Research Ethics Committee of the
Canton Zurich recently refused permission for the centre to
participate in the REPLACE trial (a prospective, randomized,
placebo-controlled study investigating fibrinogen concentrate
to control bleeding during cardiac surgery), as they considered
it unethical to expose patients in the control arm to unneces-
sary FFP transfusions when patients outside the context of
the study were receiving fibrinogen concentrate according to
the institutional algorithm-based coagulation management
guidelines, by which theirexposure to blood products is reduced.
Another point that warrants clarification is the authors’
description of infusion times. The authors suggest that
mixing of fibrinogen concentrate takes 15 min; in fact, the
manufacturer suggests this takes only 5–10 min. The
authors also underestimate the amount of time it takes to
prepare FFP and cryoprecipitate; these products take time to
be ordered, tested for blood group compatibility (where neces-
sary), and prepared for administration. Not every hospital has
access to equipment to allow them to thaw frozen products in
,15 min, as suggested by the authors of the review, and
thawing takes 45 min at room temperature.24 Taking all these
factors into account, the entire blood product preparation
process can take 60–90 min.24 25 Pre-thawed or liquid (never
frozen) plasmas can be used; however, these products are of
limited availability, and are generally only accessible in a
small number of large, tertiary care hospitals. The authors of
this review are correct in their assertion that there is no recom-
mended infusion rate for FFP; however, this is simply because
there is a lack of clinical evidence from which an optimal infu-
sion rate can be determined. The manufacturers of the
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commercial plasma Octaplas recommend a rate of no more
than 1 ml kg21 min21;26 infusion at rates greater than this
has been shown to result in citrate toxicity and hypocalcaemia.26
27 Using the suggested rate, for a patient of 70 kg, and assum-
ing a fibrinogen concentration for FFP of 2 g litre21,28 it would
take more than 35 min (and over 2 litre of FFP) to transfuse a
5 g fibrinogen dose. For fibrinogen concentrate, an optimal in-
fusion rate of 5 ml min21 is quoted by the manufacturers, as
determined from the results of pharmacokinetics studies and
RCTs. In a controlled setting, infusion of both fibrinogen con-
centrate and blood products should take place as slowlyas pos-
sible; however, in an emergency situation, rapid infusion may
be desirable. Studies in cardiovascular surgery have shown
that it is possible to infuse 1 g fibrinogen concentrate in ,20 s
(i.e. 250 ml min21).5 29
Finally, despite the fact that none of the studies analysed in
the Cochrane review addressed the cost–benefit issue, the
authors of the Cochrane review chose to discuss the current
cost of fibrinogen concentrate in one country, Denmark.
However, the authors chose to quote the retail price of 657E,
which includes both the margins added by the pharmacy and
the VAT; it would be more appropriate to quote the pharmacy
purchase price, which in Denmark is currently 479E.30 The
authors also failed to consider that costs will vary widely from
region to region and are dependent upon a number of factors,
such as the tax and healthcare systems of each individual
country. Therefore, picking a price in just one European country
to use as an example is of little benefit to the international read-
ership of the Cochrane review. In addition, the authors neglected
to discussthe equivalent costs of the alternatives, that is, FFPand
cryoprecipitate. Without such a comparison, anystated costs are
irrelevant and uninformative. In fact, determining the cost of
allogeneics is a highly complex issue in need of detailed analysis,
as the true cost of blood products is far higher than the direct ac-
quisition cost of the product itself; indirect costs such as
storage, preparation, thawing, processing, and compatability
testing also have to be taken into account.31 A previous
discussion regarding the price of allogeneics in Sweden
prompted the suggestion that health economics would
benefit from the input of both clinicians and economists, as
neither are in a position to fully understand all of the facts.32
In conclusion, we feel that the Cochrane review contains in-
formation that may mislead readers. Systematic reviews such
as this should provide clear, unambiguous recommendations
for clinicians to follow, and these recommendations should
be clearly justified, particularly when they relate to a licensed
product with a broad label that is now the standard of care in
several countries. If alternative treatments are suggested,
this should be in the knowledge that they are a safe and effica-
cious option for patients, rather than simply relying on ‘tradition’
and potentially outdated treatments that have themselves
never been subjected to the appropriate research scrutiny.
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Characterization of anaesthesia is tricky, in particular, to go
beyond the usual definition of a ‘state of non-responsiveness
to various types of stimulations’, and to find indicators useful
for titrating drug administration. General anaesthesia is
usually split into two main domains: unconsciousness (non-
response to verbal stimulation and amnesia) and analgesia
(non-response to noxious stimulations).1 2 Unconsciousness
may be directly assessed at induction of anaesthesia (loss of
verbal contact) and after recovery (absence of recall), but
usually not during maintenance. The adequacy of the
balance between analgesia and stimulation can be clinically
estimated through movement, haemodynamic changes, and
autonomic nervous system responses (sweat and lacrimation,
modification in pupil diameter); these clinical endpoints have
limitations when used for titrating anaesthetic drugs in clinical
practice, specifically in paralysed patients. Furthermore, as ad-
equate anaesthesia is defined as non-responsiveness, clinical
assessment cannot distinguish between adequate drug deliv-
ery and overdosing if overdosing does not induce adverse
effects.
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